Genzyme Genetics Signs Multi-Year Renewal Agreement with CIGNA HealthCare

Date: September 16, 2008

WESTBOROUGH, Mass – Genzyme Genetics, a business unit of Genzyme Corporation, announced today that it has signed a new multi-year ancillary services agreement with CIGNA HealthCare for Genzyme’s full suite of oncology and reproductive diagnostic and predictive testing and consultative services, as well as reproductive genetic counseling—all now available to CIGNA members nationwide and in Puerto Rico. Specific terms of the agreement were not disclosed.

Additionally, Genzyme Genetics will no longer be contractually restricted from marketing itself as a fully participating, in-network provider to CIGNA HealthCare for all services in all major markets.

"We are very pleased to be extending our relationship with CIGNA, giving their enrollees and network of participating providers access to Genzyme Genetics’ extensive offerings. Through our agreement, we will continue to provide services as one of the country’s largest and most innovative laboratories for reproductive and oncology testing,” said Jon Hart, senior vice president and general manager, Genzyme Genetics. “In addition, we will provide access to over 150 board-certified genetic professionals and pathologists for consultation on difficult cases to CIGNA providers and members throughout the United States.”

About CIGNA

CIGNA HealthCare, a health service organization based in Bloomfield, Conn, works to improve the health, well-being and security of the people they serve. A leading provider of employee benefit services and programs, CIGNA HealthCare offers a broad array of medical, dental, behavioral health, and pharmacy benefits plans and coverage. The company also builds and provides health and wellness coaching programs and information tools designed to improve health and help people in their healthcare decision-making. “CIGNA HealthCare” and the “Tree of Life” logo are registered trademarks of CIGNA Intellectual Property, Inc. licensed for use by CIGNA Corporation (NYSE: CI) and its operating subsidiaries, including Connecticut General Life Insurance Company. Products and Services are provided by such operating subsidiaries, and not by CIGNA Corporation. For more information please visit www.cigna.com

About Genzyme Genetics

Genzyme Genetics is driven by its commitment to patients and offers a broad array of testing services for pathology, oncology, reproductive and genetic medicine. Twenty years of testing expertise utilizing sophisticated technologies has made Genzyme Genetics a leading worldwide provider of high-quality testing services for physicians and their patients. With an extensive network of laboratories across the United States and operations in Europe and Japan, Genzyme Genetics assists thousands of clinicians in providing the best care possible to patients. As a division of Genzyme Corporation, Genzyme Genetics contributes its resources and strengths to one of the world’s leading biotechnology companies. For more information, please visit www.genzymegenetics.com

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.